Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.
Sep 29, 2016 at 2:00 PM PT
Arbutus Biopharma HBV Product Pipeline Update
Aug 16, 2016
2016 Wedbush PacGrow Healthcare Conference